Literature DB >> 11043569

Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity.

S K Mahata1, M Mahata, A R Wakade, D T O'Connor.   

Abstract

The novel chromogranin A fragment catestatin (bovine chromogranin A(344-364); RSMRLSFRARGYGFRGPGLQL) is a potent inhibitor of catecholamine release (IC50, approximately 0.2-0.3 microM) by acting as a nicotinic cholinergic antagonist. To define the minimal active region within catestatin, we tested the potencies of synthetic serial three-residue deletion (amino-terminal, carboxyl-terminal, or bidirectional) fragments to inhibit nicotine-stimulated catecholamine secretion from PC12 pheochromocytoma cells. The results revealed that a completely active core sequence of catestatin was constituted by chromogranin A(344-364). Nicotinic cationic signal transduction was affected by catestatin fragments in a manner similar to that for secretion (confirming the functional importance of the amino-terminus). To identify crucial residues within the active core, we tested serial single amino acid truncations or single residue substitutions by alanine on nicotine-induced catecholamine secretion and desensitization. Nicotinic inhibition by the active catestatin core was diminished by even single amino acid deletions. Selective alanine substitution mutagenesis of the active core revealed important roles for Met346, Leu348, Phe350, Arg351, Arg353, Gly354, Tyr355, Phe357, and Arg358 on catecholamine secretion, whereas crucial roles to inhibit desensitization of catecholamine release were noted for Arg344, Met346, Leu348, Ser349, Phe350, Arg353, Gly354, Tyr355, Gly356, and Arg358. We conclude that a small, 15-amino acid core of catestatin (chromogranin A(344-364)) is sufficient to exert the peptide's typical inhibitory effects on nicotinic cholinergic-stimulated catecholamine secretion, signal transduction, and desensitization. These studies refine the biologically active domains of catestatin and suggest that the pharmacophores for inhibition of nicotinic secretion and desensitization may not be identical.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11043569     DOI: 10.1210/mend.14.10.0531

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  36 in total

Review 1.  Catestatin: a multifunctional peptide from chromogranin A.

Authors:  Sushil K Mahata; Manjula Mahata; Maple M Fung; Daniel T O'Connor
Journal:  Regul Pept       Date:  2010-01-28

2.  Catestatin (chromogranin A(352-372)) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling.

Authors:  Gautam K Bandyopadhyay; Christine U Vu; Stefano Gentile; Howon Lee; Nilima Biswas; Nai-Wen Chi; Daniel T O'Connor; Sushil K Mahata
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

3.  Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog.

Authors:  Nitish R Mahapatra; Daniel T O'Connor; Sucheta M Vaingankar; Amiya P Sinha Hikim; Manjula Mahata; Saugata Ray; Eugenie Staite; Hongjiang Wu; Yusu Gu; Nancy Dalton; Brian P Kennedy; Michael G Ziegler; John Ross; Sushil K Mahata
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

4.  Modulatory mechanism of the endogenous peptide catestatin on neuronal nicotinic acetylcholine receptors and exocytosis.

Authors:  Carlos J Herrero; Eva Alés; Antonio J Pintado; Manuela G López; Esther García-Palomero; Sushil K Mahata; Daniel T O'Connor; Antonio G García; Carmen Montiel
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

5.  Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin.

Authors:  Nilima Biswas; Sucheta M Vaingankar; Manjula Mahata; Madhusudan Das; Jiaur R Gayen; Laurent Taupenot; Justin W Torpey; Daniel T O'Connor; Sushil K Mahata
Journal:  Endocrinology       Date:  2007-11-08       Impact factor: 4.736

6.  Long human CHGA flanking chromosome 14 sequence required for optimal BAC transgenic "rescue" of disease phenotypes in the mouse Chga knockout.

Authors:  Sucheta M Vaingankar; Ying Li; Angelo Corti; Nilima Biswas; Jiaur Gayen; Daniel T O'Connor; Sushil K Mahata
Journal:  Physiol Genomics       Date:  2009-12-15       Impact factor: 3.107

7.  Cellular distribution of chromogranin A in excitatory, inhibitory, aminergic and peptidergic neurons of the rodent central nervous system.

Authors:  M K-H Schafer; S K Mahata; N Stroth; L E Eiden; E Weihe
Journal:  Regul Pept       Date:  2009-12-18

Review 8.  Chromogranin A: a novel susceptibility gene for essential hypertension.

Authors:  Bhavani S Sahu; Parshuram J Sonawane; Nitish R Mahapatra
Journal:  Cell Mol Life Sci       Date:  2009-11-27       Impact factor: 9.261

9.  The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism.

Authors:  Tommaso Angelone; Anna Maria Quintieri; Bhawanjit K Brar; Pauline T Limchaiyawat; Bruno Tota; Sushil K Mahata; Maria Carmela Cerra
Journal:  Endocrinology       Date:  2008-06-05       Impact factor: 4.736

Review 10.  The chromogranins: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia.

Authors:  Steven A Feldman; Lee E Eiden
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.